title: Effects of hydrocortisone on acute β-adrenoceptor blocker and histamine induced bronchoconstriction.
abstract: β-adrenoceptor blockers are avoided in asthma due to concerns of bronchoconstriction. We investigated the safety of acute exposure to propranolol in asthmatics, sequentially challenged with histamine to mimic an asthma exacerbation and evaluated the role of intravenous hydrocortisone in potentiating salbutamol reversibility.
  
  
  
  Persistent atopic asthmatics, requiring ≤ 1000 µg day(-1) budesonide, performed a randomized double-blind placebo-controlled crossover study. Following 10 mg or 20 mg of oral propranolol, patients received 400 mg intravenous hydrocortisone or placebo, followed by histamine challenge with nebulized salbutamol 5 mg and ipratropium 500 µg recovery.
  
  
  
  Thirteen patients completed per protocol. Hydrocortisone did not potentiate salbutamol recovery post propranolol and histamine challenge vs. placebo (mean difference in FEV(1) 0.04 ml, 95% CI -0.07, 0.15, P= 0.417). β-adrenoceptor blocker induced bronchoconstriction was demonstrated by spirometry and impulse oscillometry. For the placebo visit, FEV(1) fell 4.7% 2 hours post propranolol (95% CI 1.8, 7.5, P= 0.008) whilst total airway resistance (R5%) increased 31.3% (95% CI 15.6, 47.0, P= 0.04). On both visits FEV(1) % and R5% returned to baseline after salbutamol post histamine.
  
  
  
  Nebulized salbutamol and ipratropium produced a full recovery after propranolol and histamine induced bronchoconstriction, independent of hydrocortisone use. Since the greatest risk of β-adrenoceptor blockade is after first dose, our findings offer reassurance to those undertaking further evaluation of chronic β-adrenoceptor blockade as a potential treatment for mild-to-moderate asthma.
authors.affiliation: Asthma and Allergy Research Group, Centre for Cardiovascular and Lung Biology, Division of Medical Sciences, University of Dundee, Dundee, UK.
authors.forename: Philip M
authors.initials: PM
authors.lastname: Short
authors.forename: Peter A
authors.initials: PA
authors.lastname: Williamson
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Lipworth
mesh_terms: D000280:Administration, Inhalation; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D000420:Albuterol / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001249:Asthma / Q000188:drug therapy*; D001985:Bronchial Provocation Tests; D016084:Bronchoconstriction / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006632:Histamine / Q000494:pharmacology*; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology*; D007262:Infusions, Intravenous; D009241:Ipratropium / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000494:pharmacology; D055815:Young Adult
chemical_list: D000319:Adrenergic beta-Antagonists; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D006632:Histamine; D011433:Propranolol; D009241:Ipratropium; D000420:Albuterol; D006854:Hydrocortisone
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1985 Feb;328(4):417-22
references.pmid: 2859531
references.citation: Lancet. 1982 Aug 21;2(8295):444
references.pmid: 6124836
references.citation: Pulm Pharmacol Ther. 2008;21(1):134-41
references.pmid: 17703976
references.citation: Pulm Pharmacol Ther. 2008;21(1):115-24
references.pmid: 17689122
references.citation: Ann Intern Med. 2002 Nov 5;137(9):715-25
references.pmid: 12416945
references.citation: Eur Respir J. 2010 Oct;36(4):963-5
references.pmid: 20889466
references.citation: Thorax. 2011 Jun;66(6):502-7
references.pmid: 21459857
references.citation: Eur Respir J. 2005 Aug;26(2):319-38
references.pmid: 16055882
references.citation: Lancet. 1964 May 16;1(7342):1080-1
references.pmid: 14132613
references.citation: Thorax. 1980 Feb;35(2):160
references.pmid: 7376124
references.citation: Am J Med. 1994 Jul;97(1):29-37
references.pmid: 7913292
references.citation: Br J Gen Pract. 1996 Jul;46(408):423-5
references.pmid: 8776915
references.citation: Lancet. 1983 Dec 24-31;2(8365-66):1505
references.pmid: 6140598
references.citation: Lancet. 1995 Jul 22;346(8969):201-6
references.pmid: 7616798
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4948-53
references.pmid: 15069206
references.citation: Br J Clin Pharmacol. 2001 Apr;51(4):359-62
references.pmid: 11318774
references.citation: Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2435-40
references.pmid: 19171883
references.citation: Lancet. 2009 Jan 10;373(9658):104-5
references.pmid: 19135598
references.citation: Eur Respir J. 2003 Dec;22(6):1026-41
references.pmid: 14680096
references.citation: Br J Clin Pharmacol. 2004 Aug;58(2):134-41
references.pmid: 15255795
references.citation: Br J Pharmacol. 2005 Feb;144(3):317-22
references.pmid: 15655528
references.citation: Am Rev Respir Dis. 1989 Jun;139(6):1390-4
references.pmid: 2658700
references.citation: Eur J Clin Pharmacol. 1989;37(3):297-300
references.pmid: 2575521
references.citation: Am J Respir Crit Care Med. 1997 Jul;156(1):28-35
references.pmid: 9230722
references.citation: Lancet. 1964 Nov 21;2(7369):1101-2
references.pmid: 14207902
references.citation: N Engl J Med. 2001 May 31;344(22):1651-8
references.pmid: 11386263
references.citation: Br Med J (Clin Res Ed). 1981 Feb 14;282(6263):548-9
references.pmid: 6109556
references.citation: Br J Clin Pharmacol. 1994 Aug;38(2):103-8
references.pmid: 7981009